Maravai unit TriLink wins China patent for CleanCap mRNA capping technology

MRVI•2026-07-20

Coverage includes latest M6 analog

Coverage includes the latest M6 analog, extending protection for technology used in commercial COVID-19 mRNA and saRNA vaccines.

China patent strengthens CleanCap protection

Maravai LifeSciences’ TriLink unit secured a newly issued China patent for CleanCap mRNA capping technology, strengthening IP protection in a key market.

Patent ZL 2025 1 1246578.X covers co-transcriptional RNA synthesis methods using trimer or tetramer capping structures across the CleanCap analog suite.

Maravai unit TriLink wins China patent for CleanCap mRNA capping technology

Coverage includes latest M6 analog

China patent strengthens CleanCap protection

Related News

European shares inch higher as oil prices ease; earnings in focus

B&G Foods <BGS.N>: Barclays cuts target price to $5 from $6

Nasdaq trade halt continues <LAWR.O> reason not available at 03:58 am

Gold rises 1% as hopes for US-Iran diplomacy pause oil rally

Post Holdings, Inc. <POST.N>: Barclays cuts target price to $106 from $119